### **Company Overview** J B Chemicals & Pharmaceuticals Ltd (JBCPL), operating as **JB Pharma – 'Good People for Good Health'**, is a rapidly growing Indian pharmaceutical company with a strong domestic presence and expanding international footprint. Established in 1976, the company has evolved into a leading player in **cardiovascular care**, **gastroenterology**, and **specialty therapeutic areas**, including **ophthalmology**, **probiotics**, **pediatrics**, and **lozenge-based drug delivery**. In **June 2025**, JB Pharma merged with **Torrent Pharmaceuticals**, consolidating to become the **5th largest pharma company in India by secondary sales** and **4th largest by prescriptions**, with combined revenue exceeding **₹15,000 crore** and EBITDA at **₹4,800 crore**. The strategic rationale included portfolio synergies, market leadership, operational efficiencies, and expansion into high-growth chronic care and CDMO segments. JB Pharma is majority-owned by **KKR**, which acquired the company in 2020, catalyzing transformational growth through strategic acquisitions, R&D investment, digital enablement, and international diversification. --- ### **Core Markets & Geographical Presence** - **Primary Market**: India (56–58% of revenue in the merged entity), serving over **150 million patients annually**. - **Home Markets**: India is the core, with **Russia and South Africa** considered strategic "home markets" due to direct subsidiaries and long-term brand equity. - **International Footprint**: Operates in **over 40 regulated and semi-regulated markets** across the US, EU, Canada, Australia, Latin America, Africa, and Southeast Asia. - **Distribution Model**: - **Direct operations**: Russia, South Africa, UAE, Philippines, and select EU markets. - **Distributor-led**: US, Latin America, Africa, and Asia-Pacific. - **Subsidiaries**: Four international subsidiaries in **South Africa, Russia, UAE, and the Philippines**. --- ### **Financial & Operational Highlights** - **FY25 Revenue**: ₹3,918 crore (domestic formulations), with **international business contributing ~45%** of total revenue. - **Revenue CAGR**: **17%** over the last 4 years (FY21–FY25). - **Prescriptions Growth**: **17% CAGR**, outpacing the Indian Pharmaceutical Market (IPM) average. - **Market Position**: Ranks among **top 15–25** in India (by revenue and prescriptions), targeting **top 10** by FY27. - **Profitability**: Gross margin of ~65%, operating EBITDA margin of 26–28%, and strong ROCE (~21–29% historically). --- ### **Therapeutic Focus & Portfolio Strength** JB Pharma has strategically shifted toward **high-growth, chronic-care segments**, with 65–75% of domestic revenue derived from progressive therapy areas: | **Therapy** | **Key Brands** | **Growth & Positioning** | |------------------------|----------------------------------------------------------------------------------|---------------------------| | **Cardiology** | **Cilacar, Nicardia, RACIL, Cilacar T, Azmarda (Sacubitril/Valsartan), Razel (Rosuvastatin)** | **#8 in cardiac therapy** in India; **3 brands in top 25**; Cilacar T growing at 37% YoY. | | **Probiotics** | **Sporlac, Sporlac GG, Lobun, Oxalo** | Sporlac grew from ₹69 crore (FY22) to ₹134 crore (IQVIA MAT '25); now >6 mega brands generating >₹100 crore each. | | **Hypertension** | Cilacar, Cilnidipine+ARB Combination | **40% of revenue**, 20% CAGR; focuses on diabetic hypertensives with renal complications. | | **Ophthalmology** | **Simbrinza, Travatan, Vigamox, Nevanac, Travacom** | Acquired via $116M perpetual license (Novartis); targets >3 million glaucoma patients; growing 22% YoY. | | **Pediatrics** | **Z&D, Pedicloryl, Pecef, Rantac Syrup** | Portfolio grew 12–21% YoY; expanded via Dr. Reddy’s acquisition. | | **Respiratory & OTC** | Metrogyl, NEBBUDDY (digital platform), lozenges | NEBBUDDY supports 300,000+ patients with 24/7 digital guidance. | - **Mega Brands**: Six brands exceed **₹100 crore** in annual revenue; 25 brands exceed **₹20 crore**. - **Top 300 IPM Presence**: **Six** of JB Pharma’s brands rank among the **top 300** in India (per IQVIA MAT '25), including Sporlac’s entry. --- ### **Digital & Innovation Initiatives** JB Pharma has embraced digital health to enhance patient engagement and physician value: - **NEBBUDDY**: Digital patient support tool providing 24/7 video guidance in **11 regional languages** for nebulizer use, improving adherence in respiratory care. - **JB NEXT**: AI-powered digital app for doctors with clinical algorithms, drug interaction checker, and medical calculators; **10,000+ doctors onboarded** without ad spend; **14–15 min average session** duration. - **Phygital GTM Model**: Hybrid detailing, sales force automation, and digital engagement to boost field productivity. --- ### **CDMO & Manufacturing Excellence** JB Pharma is a **global leader in contract development and manufacturing (CDMO)**, particularly in **lozenges**: - **CDMO Position**: Among **top 5 global manufacturers** of **medicated and herbal lozenges**; serves **Kenvue (Zarbees), Reckitt (Strepsils), Krka, and P&G (Vicks)**. - **Revenue & Growth**: CDMO contributes **27% of international revenue** (₹432 crore in FY24); growth driven by **18% YoY increase** in Q4 FY24. - **Aspiration**: Target **$100 million revenue** from CDMO business within next 3–5 years. - **Capabilities**: - **Lozenge formats**: Centre-filled, soft-center, powder-filled, sugar-free, herbal. - **Therapeutic expansion**: Sleep, immunity, pain, motion sickness, inflammation. - **Manufacturing**: - **8 state-of-the-art plants** across Gujarat and Daman (India), producing 10+ dosage forms. - **Daman Lozenge Plant**: Fully automated, German machinery, **EU GMP, TGA (AU), SAHPRA (ZA), ANVISA (BR), EA EU**. - **Capacity**: 2 billion lozenges/year; operating at ~50% capacity, providing headroom for growth. - **API & Formulations**: Backward integration in key molecules (Diclofenac, Ciprofloxacin); 40+ global regulatory accreditations. --- ### **Strategic Acquisitions & Portfolio Expansion** JB Pharma has executed a disciplined inorganic growth strategy (5 acquisitions FY22–FY24, ~$200M invested): | **Acquisition** | **Therapeutic Area** | **Key Brands** | **Strategic Impact** | |------------------------|----------------------|------------------------------|------------------------| | **Sanzyme (Probiotics)** | Probiotics, IVF | Sporlac, Lobun, Oxalo | Entered ₹2,000 Cr probiotics market; 7.5% share; cross-leveraged GI prescribers. | | **Azmarda (Novartis)** | Heart Failure | Sacubitril + Valsartan | Strengthened cardiology; #10–15 in molecule post-LOE; 24% growth. | | **Razel (Glenmark)** | Lipid Management | Rosuvastatin (Razel) | Entered $3B+ statin market; grew to ₹100 Cr from ₹60 Cr. | | **Pediatric Brands (Dr. Reddy’s)** | Pediatrics | Z&D, Pedicloryl, Ezinapi | Gained 3 of top 3 brands in their segments; enhanced pediatric coverage. | | **Ophthalmology Portfolio (Novartis)** | Eye Care | Simbrinza, Vigamox, Nevanac | Added ₹2800 Cr TAML; projected >12% growth; margin accretive. | --- ### **R&D & Advanced Drug Delivery Technologies** - **R&D Spend**: ~1–1.5% of revenue, focused on international pipeline and product lifecycle management. - **Technological Differentiation**: - **OROS (Osmotic-controlled Release)**: One of the few Indian companies implementing this 24-hour sustained drug delivery system (e.g., Nicardia XL). - **Lozenge Platforms**: Centre-filled, delayed/extended release, floating systems. - **Multi-layer tableting, Wurster coating, laser-drilled osmotic systems**. - **Pipeline Focus**: Fixed-dose combinations (e.g., Cilnidipine with ARBs, statins), lozenges (melatonin, throat spray), and ORS solutions. --- ### **Sales & Marketing Strength** - **Field Force**: Over **5,000 employees**, including **2,800+ sales representatives in India**. - **Go-to-Market Strategy**: - **Therapy-aligned structure**: Cardiology, Pediatrics, Nephrology, Respiratory, GI. - **Productivity**: Reached **₹8 lakh PCPM** (pharmacy sales per MR/month), up from ₹4.6 lakh in FY21; targeting 10–14% annual improvement. - **Physician Coverage**: 350,000+ HCPs; 8,400+ cardiologists; 13,500+ ophthalmologists (post-octa integration). - **Brand Strategy**: Focus on **"mother franchises"** (e.g., Cilacar) and lifecycle extensions (Rantac OD, Metrogyl ER). --- ### **Supply Chain & Procurement** - **Suppliers**: 365 raw material, 154 packaging material suppliers. - **Localization**: - **65.6% of raw material spend in India** (₹430.53 crore). - **89% of packaging spend in India** (₹167.68 crore). - **Logistics**: Strong export compliance; supplies to 40+ countries with consistent on-time delivery.